Reckitt Benckiser Group PLC

Tags:

Last Updated:
Federal Trade Commission, Plaintiff, v. Reckitt Benckiser Group PLC, Defendant.
FTC Matter/File Number:

131 0036

Civil Action Number:

1:19CV00028

Enforcement Type:

Federal Injunctions

Federal Court:
Western District of Virginia

Case Summary

Reckitt Benckiser Group plc has agreed to pay $50 million to settle Federal Trade Commission charges that it violated the antitrust laws through a deceptive scheme to thwart lower-priced generic competition to its branded drug Suboxone. According to the complaint, before the generic versions of Suboxone tablets became available, Reckitt and its former subsidiary Reckitt Benckiser Pharmaceuticals, now known as Indivior, Inc., developed a dissolvable oral film version of Suboxone and worked to shift prescriptions to this patent-protected film. Worried that doctors and patients would not want to switch to Suboxone Film, Reckitt allegedly employed a “product hopping” scheme where the company misrepresented that the film version of Suboxone was safer than Suboxone tablets because children are less likely to be accidentally exposed to the film product.